January 5, 2018
Takeda Pharmaceutical intents to acquire TiGenix (Brussels and NASDAQ: TIG)
January 3, 2018
Sangamo Therapeutics (SGMO) $12 million collaboration with Pfizer (PFE) on a gene therapy for two neuro-degenerative disorders
January 2, 2018
Vericel Corporation (VCEL initiated a License Agreement with Innovative Cellular Therapeutics (ICT)
January 1, 2018
It's time to subscribe ...
December 22, 2017
Biostage (BSTG) the swindle scheme continues with a 1-for-20 reverse split ratio effective 12/22/17
December 19, 2017
Northwest Bio (NWBO) Just another Ponzi financing scheme
December 18, 2017
Biostage (BSTG): Ponzi or Pyramid scheme or a combination of both …?
December 14, 2017
Biostage (BSTG) raised $4 M with sale of 60 M shares with 100% warrant coverage
December 14, 2017
Verastem (VSTM) proposes $25 M offering
December 13, 2017
Fate Therapeutics (FATE) closes $42.9 M offering at $4.20
December 12, 2017
bluebird bio (BLUE) Prices 3.343 M share offering at $185.00
December 11, 2017
VistaGen (VTGN) closes 10 M share offering at $1.50 with 100% warrant coverage
December 7, 2017
Biostage (BSTG) de-listing determination
December 6, 2017
Biostage (BSTG) the end is in sight with a lab liquidation auction, next the lights get turned off
December 4, 2017
Northwest Biotherapeutics (NWBO) completed a $12 M financing
October 23, 2017
uniQure (QURE) proposes 5 M share offering
October 13, 2017
Biostage (BSTG) just another junk trade or a bankruptcy?
October 13, 2017
Spark Therapeutics (ONCE) big event and no appreciation as shares drop -$1.82 or -2.14%
October 12, 2017
BioTime (NYSEMKT: BTX) proposes 9.515 M share offering
October 6, 2017
Biostage (BSTG) Breech, breech … breech
September 18, 2017
Pluristem (PSTI) using stock as the collateral payments distorts your progress
June 1, 2017
Biostage (BSTG) disclosure of material information re a wrongful death complaint
May 31, 2017
Cytori (CYTX) executes $13.4 M Option for burn clinical trial with BARDA
May 12, 2017
Capricor (CAPR) bites the bullet that they fired at itself
3 hours 27 min ago
RegMed Investors (RMi) Closing Bell: sector share pricing falls from Issac Newton’s apple tree
9 hours 58 min ago
RegMed Investors (RMi) Financing: Sangamo Therapeutics (SGMO) prices 12,235 M share offering at $0.50 to raise $23 M
12 hours 18 min ago
RegMed Investors’ (RMi) pre-open: Gravity
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.